[Pharmaceutical care for severe and critically ill patients with COVID-19].

Jiang, Saiping; Li, Lu; Ru, Renping; Zhang, Chunhong; Rao, Yuefeng; Lin, Bin; Wang, Rongrong; Chen, Na; Wang, Xiaojuan; Cai, Hongliu; Sheng, Jifang; Zhou, Jianying; Lu, Xiaoyang; Qiu, Yunqing

Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on Diagnosis and treatment of novel coronavirus pneumonia (trial version 6), and Management of COVID-19: the Zhejiang experience, we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients.